Friday, February 21, 2020 9:40:14 AM
"The company has been exploring options for large scale manufacturing. Our current manufacturing capabilities are limited to less than 10,000 units per month through our small-scale manufacturing facility and R&D lab in New Jersey. We have successfully identified and aligned ourselves with two contract manufacturing organizations (CMOs). These two companies have decades of experience with manufacturing our dosage forms for Rx products, and our team has worked with them in the past. They offer us cGMP manufacturing capabilities with the ability to produce millions of units per month. This is a critical milestone for the Company to be able to achieve market penetration through our partners’ distribution channels. For partner companies needing a THC product, we have aligned ourselves with two companies that manufacture the machinery required to produce our delivery system in our partners’ facilities as opposed to in our CMOs facilities. We believe with these two options available we can now advance our commercialization strategy and begin to take products out of the lab and into the hands of consumers."
https://www.otcmarkets.com/stock/GCAN/news/The-Greater-Cannabis-Company-Provides-Corporate-Update-to-Shareholders?id=240905
You'll find out when it's paid for when they are ready to tell you or in the financial reports.
Who said they don't have tens of thousands ready for shipment?
GCAN has filled an order to Symtomax for 125K units.
GCAN Receives Purchase Order for 125,000 Units of its Oral Cannabis Patch from Symtomax
"BALTIMORE, MD, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoids products is proud to announce that it has received a purchase order for 125,000 units of its eluting transmucosal patch. GCAN’s oral patch has been shown in clinical studies to be a safe and effective way to deliver lower doses of pharmaceutical actives, while achieving high levels of bioavailability."
"The purchase order came via Greater Cannabis’ European distribution partner Symtomax. The first Oral Tabs contain 21mg of full spectrum CBD in each sachet and will be available in 5 and 30 pack boxes in berry mint flavor with additional packet sizes, formulations and flavors planned for later on in the year. Symtomax has sourced numerous retail outlets and pharmacies for the distribution of the product, and is in further discussions with major distributors in a number of European countries."
The claim that GCAN has sold 0 units or products is your claim. The company and Symtomax are claiming different. I'll believe them, but thanks.
CBD retail is dead. Find something better. JMHO.
Recent GCAN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:58:24 PM
- Form PRER14C - Information statements • Edgar (US Regulatory) • 02/26/2024 09:09:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 08:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 04:03:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 10:11:59 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM